2023 Was a tough calendar year to the biopharma field, with numerous corporations downsizing and restructuring their workforces to remain afloat. You will find signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace during the latter part of 2023 and have continued https://sites.google.com/view/bio-sites/blog